Clinical evaluation of risankizumab for Crohn's disease
This article will review risankizumab, a monoclonal antibody targeting interleukin 23 (IL-23) for the treatment of moderate to severe Crohn’s disease.
Abbvie Inc Initiative Of International Organization For The Study Risankizumab Clinical Trial Results For Co Clinical Trial Results Co Primary Endpoints Clinical Remission
Source: dovepress.com